File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Synergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G2 DNA damage checkpoint

TitleSynergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G<inf>2</inf> DNA damage checkpoint
Authors
Issue Date2020
Citation
Molecular Cancer Therapeutics, 2020, v. 19, n. 1, p. 123-134 How to Cite?
AbstractPARP inhibitors have emerged as effective chemotherapeutic agents for BRCA1/BRCA2-deficient cancers. Another DNA damage response protein, ATM, is also increasingly being recognized as a target for synthetic lethality with PARP inhibitors. As ATM functions in both cell cycle arrest and DNA repair after DNA damage, how cells respond to inhibition of ATM and PARP1 is yet to be defined precisely. We found that loss of ATM function, either in an ATM-deficient background or after treatment with ATM inhibitors (KU-60019 or AZD0156), results in spontaneous DNA damage and an increase in PARylation. When PARP1 is also deleted or inhibited with inhibitors (olaparib or veliparib), the massive increase in DNA damage activates the G2 DNA damage checkpoint kinase cascade involving ATR, CHK1/2, and WEE1. Our data indicated that the role of ATM in DNA repair is critical for the synergism with PARP inhibitors. Bypass of the G2 DNA damage checkpoint in the absence of ATM functions occurs only after a delay. The relative insensitivity of PARP1-deficient cells to PARP inhibitors suggested that other PARP isoforms played a relatively minor role in comparison with PARP1 in synergism with ATMi. As deletion of PARP1 also increased sensitivity to ATM inhibitors, trapping of PARP1 on DNA may not be the only mechanism involved in the synergism between PARP1 and ATM inhibition. Collectively, these studies provide a mechanistic foundation for therapies targeting ATM and PARP1.
Persistent Identifierhttp://hdl.handle.net/10722/307282
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 2.270
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMak, Joyce P.Y.-
dc.contributor.authorMa, Hoi Tang-
dc.contributor.authorPoon, Randy Y.C.-
dc.date.accessioned2021-11-03T06:22:18Z-
dc.date.available2021-11-03T06:22:18Z-
dc.date.issued2020-
dc.identifier.citationMolecular Cancer Therapeutics, 2020, v. 19, n. 1, p. 123-134-
dc.identifier.issn1535-7163-
dc.identifier.urihttp://hdl.handle.net/10722/307282-
dc.description.abstractPARP inhibitors have emerged as effective chemotherapeutic agents for BRCA1/BRCA2-deficient cancers. Another DNA damage response protein, ATM, is also increasingly being recognized as a target for synthetic lethality with PARP inhibitors. As ATM functions in both cell cycle arrest and DNA repair after DNA damage, how cells respond to inhibition of ATM and PARP1 is yet to be defined precisely. We found that loss of ATM function, either in an ATM-deficient background or after treatment with ATM inhibitors (KU-60019 or AZD0156), results in spontaneous DNA damage and an increase in PARylation. When PARP1 is also deleted or inhibited with inhibitors (olaparib or veliparib), the massive increase in DNA damage activates the G2 DNA damage checkpoint kinase cascade involving ATR, CHK1/2, and WEE1. Our data indicated that the role of ATM in DNA repair is critical for the synergism with PARP inhibitors. Bypass of the G2 DNA damage checkpoint in the absence of ATM functions occurs only after a delay. The relative insensitivity of PARP1-deficient cells to PARP inhibitors suggested that other PARP isoforms played a relatively minor role in comparison with PARP1 in synergism with ATMi. As deletion of PARP1 also increased sensitivity to ATM inhibitors, trapping of PARP1 on DNA may not be the only mechanism involved in the synergism between PARP1 and ATM inhibition. Collectively, these studies provide a mechanistic foundation for therapies targeting ATM and PARP1.-
dc.languageeng-
dc.relation.ispartofMolecular Cancer Therapeutics-
dc.titleSynergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G<inf>2</inf> DNA damage checkpoint-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1158/1535-7163.MCT-19-0474-
dc.identifier.pmid31597711-
dc.identifier.scopuseid_2-s2.0-85077666151-
dc.identifier.volume19-
dc.identifier.issue1-
dc.identifier.spage123-
dc.identifier.epage134-
dc.identifier.eissn1538-8514-
dc.identifier.isiWOS:000505667900011-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats